Dr. Reddy's: Rivaksored (INN rivaroxaban)

2025: Entering the Russian Market

Company LLC "Dr. Reddy's Laboratories on February 25, 2025 announced the launch on the market of the Russian Federation of the drug Rivaksored (INN rivaroxaban), a generic of the most prescribed anticoagulant among Russian cardiologists and therapists. Rivaxore® will be available in pharmacies from February 2025 and will be available on prescription.

With longer life expectancy and better quality of care, the burden of cardiovascular disease (CVD), particularly those such as atrial fibrillation (AF), is increasing. AF is the most commonly reported clinically significant arrhythmia both worldwide and in the patient population in Russia. The prevalence of all forms of AF is 2-5% among the adult population, but with age it increases significantly - to 9.6-17.8% in people 80 years and older. The proportion of individuals using anticoagulants is calculated to be about 2% of the total population.

The most important problem for patients with AF is the high risk of ischemic stroke (AI) and systemic thromboembolism, which are most often of cardioembolic origin, which is associated with thrombus formation in the ear, less often - the left atrial cavity. In the structure of all thromboembolic complications in patients with AF, more than 90% are AI. Among AI, cardioembolic has the worst prognosis, due to high mortality and the development of persistent disability. Patients with non-valvular AF who have not previously received anticoagulant therapy are recommended to prescribe direct oral anticoagulants (POAC), including rivaroxaban, as first-line drugs.

Rivaroxaban is used in patients with an increased risk of thrombosis - the formation of blood clots in the lumen of blood vessels that supply vital organs, or thromboembolism - blockages of the vessel by a thrombus formed in another vessel (for example, in the veins of the legs). LP suppresses coagulation factor (factor Xa) and reduces the formation of a substance called thrombin, which leads to a decrease in the formation of blood clots in blood vessels. Rivaroxaban does not inhibit thrombin activity and does not affect blood plates (platelets).

Rivaxored (INN rivaroxaban) is indicated for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation of non-valvular origin and the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of relapse of DVT and PE in adults. It is authorized for admission in children and adolescents under the age of 18 for the treatment of venous thromboembolism (VTE) and the prevention of VTE relapses.

The dose of Rivaxored is individually adjusted and adjusted by the treating physician. To prevent blood clots in brain vessels (prevention of stroke) and other blood vessels (systemic thromboembolism) in adults, the recommended dose of Rivaxored is 20 mg (1 tablet) 1 times a day. If there are kidney diseases, the doctor may reduce the dose to 1 tablets 15 mg 1 once a day. For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as for the prevention of repeated blood clots (prevention of DVT and PE relapses) in adults, the recommended initial dose of Rivaxored is 15 mg (1 tablet) 2 times a day in the first three weeks. From week 4, the recommended dose is 1 tablet 20 mg 1 once a day. After 6 months of taking the drug (prolonged prevention of relapses), the doctor can reduce the dose to 1 tablets 10 mg 1 once a day, or leave the previous prescription.